

**S1 Table.** Risk of the first recurrence with intracranial recurrence (with or without extracranial recurrence) and first recurrence with extracranial recurrence (without intracranial recurrence) based on a competing risk regression model.

Characteristics (comparison vs. reference)	First recurrence with intracranial recurrence (with or without extracranial recurrence)			First recurrence with extracranial recurrence (without intracranial recurrence)		
	HR	95% CI	p-value	HR	95% CI	p-value
Prophylactic cranial irradiation (yes vs. no)	0.476	0.243-0.931	<b>0.030</b>	0.894	0.593-1.347	0.591
Age (> 70 vs. ≤ 70 yr)	1.071	0.523-2.105	0.850	0.992	0.680-1.447	0.966
Sex (male vs. female)	1.374	0.539-3.507	0.506	1.312	0.810-2.125	0.269
Smoking (yes vs. no)	1.952	0.695-5.484	0.204	0.977	0.624-1.529	0.919
FEV <sub>1</sub> /FVC (< 70% vs. ≥ 70%)	1.638	0.808-3.323	0.171	1.135	0.800-1.608	0.478
ECOG performance status (2-3 vs. 0-1)	1.197	0.363-3.953	0.767	1.188	0.663-2.132	0.562
Initial neuron-specific enolase (> 16.3 vs. ≤ 16.3 ng/mL)	0.974	0.448-2.120	0.948	0.994	0.686-1.442	0.976
Initial neutrophil-lymphocyte ratio (> 3.53 vs. ≤ 3.53)	1.798	0.874-3.697	0.111	1.102	0.708-1.718	0.666
Disease stage (III vs. I-II)	1.886	0.749-4.751	0.178	1.458	0.960-2.215	0.077
Chemoradiation sequence (sequential vs. concurrent)	1.320	0.597-2.912	0.494	1.401	0.927-2.117	0.110
Treatment response (SD vs. CR-PR)	1.290	0.673-2.471	0.443	1.849	1.342-2.548	<b>&lt; 0.001</b>

CI, confidence interval; CR, complete response; ECOG, Eastern Cooperative Oncology Group; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; HR, hazard ratio; PR, partial response; SD, stable disease.